[Efficacy of the combination drug vasobral in chronic vascular encephalopathy].

Abstract

OBJECTIVE:

Despite the high prevalence of chronic vascular encephalopathy, its diagnosis and treatment remain understudied. This observational multicenter trial assessed the efficacy and safety of vasobral in patients with cerebral ischemia.

MATERIAL AND METHODS:

The open observational study was carried out in 37 centers in 11 Russian cities and included 300 patients with confirmed diagnosis of chronic vascular encephalopathy, stages 1 and 2, without dementia. The patients received 1 tablet (4 mg α-dihydroergocryptine and 40 mg caffeine) 2 times a day during 3 months.

RESULTS AND CONCLUSION:

There was an improvement of cognitive and affective status as well as quality of life and a decrease of subjective signs of chronic vascular encephalopathy. Vasobral did not cause significant fluctuations of arterial pressure and was safe for patients with chronic vascular encephalopathy and arterial hypertension.

• Authors: O S Levin, E R Barantsevich, G N Belskaya, E E Vasenina, S V Kopishinskaya, I G Lukashevich, O D Ostroumova, O V Psokhina, M A Radiuk
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 114 Issue 10 Pg. 25-9 ( 2014) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 25591512 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Observational Study)

Chemical References

• Drug Combinations
• Dihydroergotoxine
• Caffeine
• Vasobral

Topics

• Adult
• Aged
• Brain Damage, Chronic (drug therapy)
• Brain Ischemia (drug therapy)
• Caffeine (adverse effects, therapeutic use)
• Cerebral Small Vessel Diseases (drug therapy)
• Dihydroergotoxine (adverse effects, therapeutic use)
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Treatment Outcome